Abstract
Malaria remains a major global health challenge, particularly in tropical and subtropical regions. The emergence of drug-resistant Plasmodium species has rendered many first-line antimalarial therapies less effective, highlighting the urgent need for new drugs. This article discusses recent advances in the development of novel antimalarial agents, including new chemical entities, repurposed drugs, and innovative delivery systems. It also explores the mechanisms of resistance, targets for drug development, and the future landscape of antimalarial pharmacotherapy.
All articles published in the American Journal of Pharmacy and Pharmacology are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows others to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given to the original author(s) and source, a link to the license must be provided, and any changes made must be indicated.
By submitting their work, authors agree to these licensing terms and retain copyright of their articles.